Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 12, 2018. The document serves as a transaction notification regarding dealings by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction.
| Metric | Value |
|---|---|
| Transaction Type | Exercise of options and subsequent sale of shares |
| Instrument | Ordinary Shares (25 pence each) |
| Volume | 2,250 shares |
| Exercise Price | £11.47 |
| Sale Price | £12.9258 |
| Transaction Date | February 12, 2018 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine insider transaction involving the exercise of share options granted in 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a PDMR transaction.
Important Facts for Investors
- Insider Identity: The transaction involved Mr. R G Connor, President of Global Manufacturing & Supply.
- Transaction Nature: Mr. Connor exercised options over 2,250 shares and immediately sold them on the London Stock Exchange.
- Financial Impact: The sale price (£12.9258) exceeded the exercise price (£11.47), indicating a realized gain on the options.
- Scope: This filing does not contain quarterly or annual financial performance data.